{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=OBIZUR&page=2",
    "query": {
      "intervention": "OBIZUR",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=OBIZUR&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T17:52:50.290Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06883240",
      "title": "An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Von Willebrand Disease, Type 3"
      ],
      "interventions": [
        {
          "name": "Von Willebrand Factor Concentrates",
          "type": "DRUG"
        },
        {
          "name": "Von Willebrand Factor Concentrates and Factor VIII Concentrates",
          "type": "DRUG"
        },
        {
          "name": "Factor VIII Concentrates",
          "type": "DRUG"
        },
        {
          "name": "Recombinant Activated Factor VII",
          "type": "DRUG"
        },
        {
          "name": "Activated Prothrombin Complex Concentrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2025-04-29",
      "completion_date": "2026-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-09-28T17:52:50.290Z",
      "location_count": 3,
      "location_summary": "Sacramento, California • Minneapolis, Minnesota • St Louis, Missouri",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06883240"
    },
    {
      "nct_id": "NCT02506023",
      "title": "Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Desmopressin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 60 Years · Female only"
      },
      "enrollment_count": 2,
      "start_date": "2015-07",
      "completion_date": "2018-06-15",
      "has_results": false,
      "last_update_posted_date": "2018-07-16",
      "last_synced_at": "2026-09-28T17:52:50.290Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02506023"
    },
    {
      "nct_id": "NCT04303572",
      "title": "The Hemophilia Inhibitor Eradication Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A With Inhibitor"
      ],
      "interventions": [
        {
          "name": "Eloctate ITI",
          "type": "DRUG"
        },
        {
          "name": "Emicizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Margaret Ragni",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 1,
      "start_date": "2021-11-01",
      "completion_date": "2022-06-27",
      "has_results": true,
      "last_update_posted_date": "2023-02-21",
      "last_synced_at": "2026-09-28T17:52:50.290Z",
      "location_count": 2,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04303572"
    },
    {
      "nct_id": "NCT03370172",
      "title": "A Study of BAX 888 in Male Adults With Severe Hemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "BAX 888",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "18 Years to 75 Years · Male only"
      },
      "enrollment_count": 4,
      "start_date": "2018-02-27",
      "completion_date": "2024-07-09",
      "has_results": true,
      "last_update_posted_date": "2025-09-11",
      "last_synced_at": "2026-09-28T17:52:50.290Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Sacramento, California + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03370172"
    },
    {
      "nct_id": "NCT00245245",
      "title": "Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "recombinant porcine coagulation factor VIII (OBI-1)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Octagen Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2005-05",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2007-10-04",
      "last_synced_at": "2026-09-28T17:52:50.290Z",
      "location_count": 1,
      "location_summary": "Blue Bell, Pennsylvania",
      "locations": [
        {
          "city": "Blue Bell",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00245245"
    },
    {
      "nct_id": "NCT04684940",
      "title": "Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia A With Inhibitor",
        "Hemophilia A With Anti Factor VIII"
      ],
      "interventions": [
        {
          "name": "Valoctocogene roxaparvovec",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BioMarin Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 10,
      "start_date": "2020-12-10",
      "completion_date": "2026-04-20",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-09-28T17:52:50.290Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04684940"
    },
    {
      "nct_id": "NCT03103542",
      "title": "Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Recombinant coagulation factor (rFVIIIFc)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Swedish Orphan Biovitrum",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 16,
      "start_date": "2017-08-29",
      "completion_date": "2020-08-31",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-09-28T17:52:50.290Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03103542"
    },
    {
      "nct_id": "NCT06349473",
      "title": "A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants",
        "Hemophilia A",
        "Hemophilia B",
        "Factor VII Deficiency"
      ],
      "interventions": [
        {
          "name": "SR604",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Equilibra Bioscience LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 31,
      "start_date": "2024-05-10",
      "completion_date": "2026-09-28",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-09-28T17:52:50.290Z",
      "location_count": 9,
      "location_summary": "Glendale, California • Los Angeles, California • Chicago, Illinois + 6 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06349473"
    },
    {
      "nct_id": "NCT01561391",
      "title": "Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Haemophilia A With Inhibitors",
        "Haemophilia B With Inhibitors"
      ],
      "interventions": [
        {
          "name": "activated recombinant human factor VII",
          "type": "DRUG"
        },
        {
          "name": "factor IX",
          "type": "OTHER"
        },
        {
          "name": "factor VIII",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "1998-04",
      "completion_date": "2004-05",
      "has_results": false,
      "last_update_posted_date": "2023-12-29",
      "last_synced_at": "2026-09-28T17:52:50.290Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01561391"
    },
    {
      "nct_id": "NCT05181618",
      "title": "A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Severe Hemophilia A",
        "Moderate Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Emicizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "13 Years to 69 Years"
      },
      "enrollment_count": 136,
      "start_date": "2022-06-20",
      "completion_date": "2027-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-09-28T17:52:50.290Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Miami, Florida • Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05181618"
    }
  ]
}